

IX BIOPHARMA LTD.

(Company Registration No. 200405621W)
(Incorporated in the Republic of Singapore)

RESULTS OF ANNUAL GENERAL MEETING

Pursuant to Rule 704(15) of the Listing Manual Section B: Rules of Catalist of the Singapore Exchange Securities Trading Limited (“**Catalist Rules**”), the Board of Directors (the “**Board**”) of iX Biopharma Ltd. (the “**Company**”) is pleased to announce that at the Annual General Meeting (“**AGM**”) of the Company held by electronic means today, all resolutions set out in the Notice of AGM dated 29 September 2021 were duly passed by way of a poll vote.

(a) The results of the poll on each of the resolutions put to the vote at the AGM are set out below:

| Resolution number and details | Total number of shares represented by votes for and against the relevant resolution | For | | Against | |
|--|---|------------------|---|------------------|---|
| | | Number of Shares | As a percentage of total number of votes for and against the resolution (%) | Number of Shares | As a percentage of total number of votes for and against the resolution (%) |
| <u>Resolution 1</u> Adoption of Directors’ Statement and the Audited Financial Statements for the financial year ended 30 June 2021 together with the Auditors’ Report thereon. | 417,418,257 | 416,857,257 | 99.87 | 561,000 | 0.13 |
| <u>Resolution 2</u> Re-election of Mr. Albert Ho Shing Tung as a Director of the Company. | 408,451,552 | 407,890,552 | 99.86 | 561,000 | 0.14 |
| <u>Resolution 3</u> Approval for payment of Directors’ fees of S\$334,000 for the financial year ending 30 June 2022, to be paid quarterly in arrears. | 417,418,257 | 416,857,257 | 99.87 | 561,000 | 0.13 |

| Resolution number and details | Total number of shares represented by votes for and against the relevant resolution | For | | Against | |
|---|---|------------------|---|------------------|---|
| | | Number of Shares | As a percentage of total number of votes for and against the resolution (%) | Number of Shares | As a percentage of total number of votes for and against the resolution (%) |
| <u>Resolution 4</u> Re-appointment of Messrs PricewaterhouseCoopers LLP as Auditors and to authorise the Directors to fix their remuneration. | 417,417,257 | 416,857,257 | 99.87 | 560,000 | 0.13 |
| <u>Resolution 5</u> Authority to allot and issue shares. | 417,418,257 | 416,857,257 | 99.87 | 561,000 | 0.13 |
| <u>Resolution 6</u> Authority to allot and issue shares under the iX Employee Share Option Scheme. | 417,418,257 | 416,857,257 | 99.87 | 561,000 | 0.13 |
| <u>Resolution 7</u> Authority to allot and issue shares under the iX Performance Share Plan. | 417,418,257 | 416,857,257 | 99.87 | 561,000 | 0.13 |
| <u>Resolution 8</u> The Proposed Grant of an Award to Mr. Eddy Lee Yip Hang, a controlling shareholder of the Company, under the iX Performance Share Plan | 222,057,656 | 221,496,656 | 99.75 | 561,000 | 0.25 |

(b) Details of parties who are required to abstain from voting

Details of parties who are required to abstain from voting on Resolution 8:

| Resolution no. | Name | No. of shares |
|--|--|----------------------|
| <u>Resolution 8</u> | Mr. Eddy Lee Yip Hang | 176,677,351 |
| The Proposed Grant of an Award to Mr. Eddy Lee Yip Hang, a controlling shareholder of the Company, under the iX Performance Share Plan | Ms. Tang Choy Leng Jane (an Associate of Mr. Eddy Lee Yip Hang) | 18,683,250 |

(c) Audit Committee - Statement Pursuant to Rule 704(7) of the Catalist Rules:

Mr. Albert Ho Shing Tung having been re-elected as a Director of the Company at the AGM, remain as a member of the Audit Committee, Remuneration Committee and Risk Management Committee. Mr. Albert Ho Shing Tung is considered to be non-independent for the purposes of Rule 704(7) of the Catalist Rules.

(d) Name of firm and/or person appointed as scrutineer:

Janusys Consultants Pte Ltd was appointed as the independent scrutineer of the AGM.

By Order of the Board

Lee Wei Hsiung / Wang Shin Lin, Adeline
Company Secretaries

15 October 2021

This announcement has been prepared by the Company and its contents have been reviewed by the Company's sponsor, UOB Kay Hian Private Limited (the "Sponsor") for compliance with the relevant rules of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalist.

This announcement has not been examined or approved by the SGX-ST and the SGX-ST assumes no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr Lance Tan, Senior Vice President at 8 Anthony Road, #01-01, Singapore 229957, telephone (65) 6590 6881.